Примери за използване на Combination products на Английски и техните преводи на Български
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Computer
the compatibility of different active substances with each other in the case of combination products, shall be documented.
the compati bility of different active substances with each other in the case of combination products, shall be documented.
unless sound justification can be provided that the combination is in line with responsible use principles, combination products should be withdrawn.”.
bromhexine-containing products are associated with an increased risk of SCARs including combination products.
In line with the regulatory requirements(CHMP/ EWP/ 191583/ 2005), a formal proof of bioequivalence, evidence of a wide therapeutic experience, and an adequately established benefit/ risk ratio should be demonstrated for new fixed dose combination products claiming substitution indication.
However, no benefit could be demonstrated of using colistin combination products over monotherapy and no feasible risk mitigation measures could be identified to address the identified potential risk for human health, as even a limited use of colistin combination products was considered an unnecessary use of colistin.
which is not the case for the other substances in combination products, in view of the withdrawal periods generally approved for products containing trimethoprim
It is recognised that colistin combination products could be efficacious for the treatment
as well as reduced levels of resistance to several other antimicrobials used in colistin combination products, despite the wide use of these products in the EU for some years.
taking into account the range of combination products included in the procedure.
According to the CHMP Guideline on combination products,“combination packs would only be acceptable in exceptional cases,
applies to all pour-on combination products containing triclabendazole(i.e. triclabendazole and moxidectin).
other scientifically acceptable studies, as to clinical scenarios where colistin combination products are essential for food-producing animals in the EU compared to monotherapy products; .
other scientifically acceptable studies, as to clinical scenarios where colistin combination products are essential for food-producing animals in the EU compared to monotherapy products. .
This combination product is not approved for these other uses.
EPS combination product of impact sound insulation
Antidiarrheal combination product.
However, concerns were raised whether gastrointestinal indications for colistin combinations products are justified when it would be more prudent to use a monotherapy product. .
For gastrointestinal indications, there are also concerns if colistin combinations products are necessary over monotherapy.
Since Atripla is a fixed- dose combination product, the dose of efavirenz cannot be altered;